Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1828 1
1891 1
1912 1
1913 1
1928 1
1937 1
1946 2
1947 3
1948 5
1949 4
1950 3
1951 2
1952 3
1953 2
1954 4
1955 1
1958 2
1959 4
1960 2
1961 1
1962 7
1963 4
1964 9
1965 4
1966 2
1967 6
1968 2
1969 2
1970 3
1971 7
1972 10
1973 10
1974 11
1975 9
1976 12
1977 12
1978 15
1979 12
1980 13
1981 17
1982 20
1983 13
1984 14
1985 13
1986 9
1987 14
1988 23
1989 20
1990 14
1991 30
1992 21
1993 33
1994 39
1995 30
1996 49
1997 31
1998 37
1999 37
2000 46
2001 48
2002 29
2003 51
2004 47
2005 46
2006 57
2007 44
2008 43
2009 46
2010 72
2011 81
2012 115
2013 109
2014 118
2015 158
2016 185
2017 154
2018 188
2019 176
2020 175
2021 166
2022 148
2023 137
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

2,854 results

Results by year

Filters applied: . Clear all
Page 1
Autism Spectrum Disorder: A Review.
Hirota T, King BH. Hirota T, et al. Among authors: king bh. JAMA. 2023 Jan 10;329(2):157-168. doi: 10.1001/jama.2022.23661. JAMA. 2023. PMID: 36625807 Review.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Medical Treatment of Benign Prostatic Hyperplasia.
Plochocki A, King B. Plochocki A, et al. Among authors: king b. Urol Clin North Am. 2022 May;49(2):231-238. doi: 10.1016/j.ucl.2021.12.003. Epub 2022 Mar 22. Urol Clin North Am. 2022. PMID: 35428429 Review.
Janus kinase inhibitors for alopecia areata.
King BA, Craiglow BG. King BA, et al. J Am Acad Dermatol. 2023 Aug;89(2S):S29-S32. doi: 10.1016/j.jaad.2023.05.049. J Am Acad Dermatol. 2023. PMID: 37591562 Review.
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Ezzedine K, et al. Among authors: king b. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36370907 Free article. Clinical Trial.
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. King B, et al. Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14. Lancet. 2023. PMID: 37062298 Clinical Trial.
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.
Illes P, Müller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C, Schmalzing G, Jarvis MF, Stojilkovic SS, King BF, Di Virgilio F. Illes P, et al. Among authors: king bf. Br J Pharmacol. 2021 Feb;178(3):489-514. doi: 10.1111/bph.15299. Epub 2020 Dec 21. Br J Pharmacol. 2021. PMID: 33125712 Free PMC article. Review.
Hospitalizations and Deaths Associated with EVALI.
Werner AK, Koumans EH, Chatham-Stephens K, Salvatore PP, Armatas C, Byers P, Clark CR, Ghinai I, Holzbauer SM, Navarette KA, Danielson ML, Ellington S, Moritz ED, Petersen EE, Kiernan EA, Baldwin GT, Briss P, Jones CM, King BA, Krishnasamy V, Rose DA, Reagan-Steiner S; Lung Injury Response Mortality Working Group. Werner AK, et al. Among authors: king ba. N Engl J Med. 2020 Apr 23;382(17):1589-1598. doi: 10.1056/NEJMoa1915314. N Engl J Med. 2020. PMID: 32320569 Free PMC article.
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, Wong K, Pathuri S, Briand J, Steidel M, Chapman P, Groy A, Wiseman AK, McHugh CF, Campobasso N, Graves AP, Fairweather E, Werner T, Raoof A, Butlin RJ, Rueda L, Horton JR, Fosbenner DT, Zhang C, Handler JL, Muliaditan M, Mebrahtu M, Jaworski JP, McNulty DE, Burt C, Eberl HC, Taylor AN, Ho T, Merrihew S, Foley SW, Rutkowska A, Li M, Romeril SP, Goldberg K, Zhang X, Kershaw CS, Bantscheff M, Jurewicz AJ, Minthorn E, Grandi P, Patel M, Benowitz AB, Mohammad HP, Gilmartin AG, Prinjha RK, Ogilvie D, Carpenter C, Heerding D, Baylin SB, Jones PA, Cheng X, King BW, Luengo JI, Jordan AM, Waddell I, Kruger RG, McCabe MT. Pappalardi MB, et al. Among authors: king bw. Nat Cancer. 2021 Oct;2(10):1002-1017. Epub 2021 Sep 27. Nat Cancer. 2021. PMID: 34790902 Free PMC article.
2,854 results